Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles

Ruiling Xu; Junhui Sui; Mingda Zhao; Yuedi Yang; Lei Tong; Yongmei Liu; Yong Sun; Yujiang Fan; Jie Liang; Xingdong Zhang

Polymer Testing (Sep 2022)

Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles

Ruiling Xu,
Junhui Sui,
Mingda Zhao,
Yuedi Yang,
Lei Tong,
Yongmei Liu,
Yong Sun,
Yujiang Fan,
Jie Liang,
Xingdong Zhang

Affiliations

Ruiling Xu: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Junhui Sui: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; The Key Laboratory of Biomedical Material, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, China
Mingda Zhao: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Yuedi Yang: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Lei Tong: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Yongmei Liu: Department of Thoracic Oncology, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, Sichuan, 610064, China; Corresponding author.
Yong Sun: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Yujiang Fan: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China
Jie Liang: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; Sichuan Testing Centre for Biomaterials and Medical Devices, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; Corresponding author. National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China.
Xingdong Zhang: National Engineering Research Center for Biomaterials, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China; College of Biomedical Engineering, Sichuan University, No.29 Wangjiang Road, Chengdu, Sichuan, 610064, China

Journal volume & issue: Vol. 113
p. 107669

Abstract

Read online

Human epidermal growth factor receptor-2 (HER-2) positive breast cancer is highly invasive with poor clinical outcomes and high risk of recurrence. Here, trastuzumab functionalized pullulan-doxorubicin nanoparticles (Tz-P-Dox) were developed and characterized as a new anticancer formulation for active targeting HER-2 overexpression of breast cancer cells. The obtained nanoparticles had the hydrodynamic diameter of 66.7 ± 2.0 nm and PDI of 0.218 ± 0.012. And the in vitro results showed significant difference of cell uptake and cytotoxic effect between Tz-P-Dox and non-targeted P-Dox against HER-2 positive cell lines (BT474 and MCF-7 cells). However, the differences between Tz-P-Dox and P-Dox were not observed in HER-2 negative cell lines (MDA-MB-231 cells). These results suggested that trastuzumab functionalized nanoparticles had great potential to be considered as a candidate drug for HER-2 positive breast cancer treatment.

Published in Polymer Testing

ISSN: 0142-9418 (Print); 1873-2348 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Technology: Chemical technology: Polymers and polymer manufacture
Website: https://www.journals.elsevier.com/polymer-testing

About the journal

Abstract

Keywords